We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Onyx Pharmaceuticals, Inc. (MM) | NASDAQ:ONXX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 124.70 | 0 | 01:00:00 |
Celsion Corporation (CLSN) recently announced that the independent Data Monitoring Committee (DMC) completed its last intermediate review of the pivotal phase III HEAT study being conducted with ThermoDox for hepatocellular carcinoma (HCC).
The DMC, after its review, recommended that the HEAT study can be continued as per schedule. Top-line data from the study is expected shortly.
The phase III HEAT study is evaluating ThermoDox in combination with radiofrequency ablation (RFA) for the treatment of HCC. The primary objective of the study is progression-free survival (PFS).
The study is conducted under the US Food and Drug Administration’s (FDA) Special Protocol Assessment (SPA). The study has received Fast Track Designation and was declared as priority trial for liver cancer by the National Institutes of Health.
In May this year, Celsion completed the enrollment process for the study. The independent DMC reviewed 701 enrolled patients in the trial. For unblinding and planned final analysis of the study, a total of 380 PFS events are required, which Celsion expects to achieve by year-end.
ThermoDox enjoys orphan drug designation both in the US and the EU. We remind investors that in December 2011, the European Medicines Agency (EMA) stated that Celsion can submit a marketing authorization application (MAA) on the basis of results from the HEAT study.
The HEAT study is being conducted in the US, Canada, Italy, China, Taiwan, Hong Kong, Korea, Thailand, Malaysia and the Philippines. Celsion is also looking for additional indications of the candidate including other tumors.
Currently, the HCC market has drugs like Bayer AG (BAYRY)/Onyx Pharmaceuticals, Inc.’s (ONXX) Nexavar and Pfizer Inc.’s (PFE) Sutent.
Our Recommendation
We currently have a Neutral recommendation on Celsion. The stock carries a Zacks #2 Rank (Buy rating) in the short run.
1 Year Onyx Pharmaceuticals, Inc. (MM) Chart |
1 Month Onyx Pharmaceuticals, Inc. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
